Literature DB >> 16490686

Fibrinolysis and cardiovascular risk factors: association with fibrinogen, lipids, and monocyte count.

Karim Zouaoui Boudjeltia1, Michel Guillaume, Charles Henuzet, Paul Delrée, Philippe Cauchie, Claude Remacle, Jean Ducobu, Michel Vanhaeverbeek, Dany Brohée.   

Abstract

BACKGROUND: Numerous risk factors for cardiovascular disease (CVD) have been determined by clinical epidemiological observations. The missing link could be related to endothelial dysfunction and the resulting hypofibrinolysis.
METHODS: In this cross-sectional study, we evaluated 160 subjects (134 in primary prevention) characterized by their clinical cardiovascular risk factors (CVRF), i.e., age, gender, diabetes, hypertension, smoking habit, and history of coronary event or stroke, and by their blood parameters, i.e., C-reactive protein (CRP), fibrinogen, leukocyte count (WBC), monocyte count (MC), total cholesterol, HDL cholesterol (HDL-c), LDL cholesterol (LDL-c), and triglycerides. We assessed their fibrinolytic capacity with a new method, Euglobulin Clot Lysis Time (ECLT). The effects of these clinical and biological parameters were evaluated in multivariate analysis (backward stepwise regression).
RESULTS: ECLT was correlated with the Framingham risk score and was significantly influenced by the number of clinical CVRF. MC was confirmed to be an important predictive factor influencing ECLT. In subjects without clinical CVRF (n=46), 67% of the variability of ECLT was explained by a combination of MC, LDL-c, and fibrinogen.
CONCLUSION: ECLT is related to the number of epidemiologically defined clinical CVRF and to MC. Because it integrates many risk factors, we suggest that fibrinolytic function could be a biological test useful for physicians in the cardiovascular risk assessment of their patients.

Entities:  

Year:  2006        PMID: 16490686     DOI: 10.1016/j.ejim.2005.11.002

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  Investigating the two regimes of fibrin clot lysis: an experimental and computational approach.

Authors:  Franck Raynaud; Alexandre Rousseau; Daniel Monteyne; David Perez-Morga; Karim Zouaoui Boudjeltia; Bastien Chopard
Journal:  Biophys J       Date:  2021-08-10       Impact factor: 3.699

2.  Background diet and fat type alters plasma lipoprotein response but not aortic cholesterol accumulation in F1B Golden Syrian hamsters.

Authors:  Alice Dillard; Nirupa R Matthan; Nicole L Spartano; Ann E Butkowski; Alice H Lichtenstein
Journal:  Lipids       Date:  2013-10-06       Impact factor: 1.880

3.  Use of hamster as a model to study diet-induced atherosclerosis.

Authors:  Alice Dillard; Nirupa R Matthan; Alice H Lichtenstein
Journal:  Nutr Metab (Lond)       Date:  2010-12-10       Impact factor: 4.169

4.  Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis.

Authors:  Karim Zouaoui Boudjeltia; Jalil Daher; Pierre Van Antwerpen; Nicole Moguilevsky; Paul Delree; Jean Ducobu; Martine Raes; Bassam Badran; Michel Vanhaeverbeek; Dany Brohee; Claude Remacle; Luc Vanhamme
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

5.  Plasma fibrinolysis is related to the degree of organ dysfunction but not to the concentration of von Willebrand Factor in critically ill patients.

Authors:  Karim Zouaoui Boudjeltia; Sandra Ollieuz; Michael Piagnerelli; Patrick Biston; Philippe Cauchie; Jean-Louis Vincent; Dany Brohee; Michel Vanhaeverbeek
Journal:  Thromb J       Date:  2009-06-19

Review 6.  Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.

Authors:  Cédric Delporte; Pierre Van Antwerpen; Luc Vanhamme; Thierry Roumeguère; Karim Zouaoui Boudjeltia
Journal:  Mediators Inflamm       Date:  2013-07-24       Impact factor: 4.711

7.  Pathophysiologic mechanisms of cardiovascular disease in obstructive sleep apnea syndrome.

Authors:  Carlos Zamarrón; Luis Valdés Cuadrado; Rodolfo Alvarez-Sala
Journal:  Pulm Med       Date:  2013-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.